Medicus Pharma Ltd. Commo... (MDCX)

Medicus Pharma (NASDAQ:MDCX) reported that it has completed its previously announced acquisition of Antev Limited, a UK-based clinical-stage drug development company.  Medicus said it has acquired 98....

Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 b...

Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shar...

US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patients Philadelphia, Pennsylvania--(Newsfile Corp...

Medicus Pharma (NASDAQ:MDCX) has agreed a non-binding memorandum of understanding with Boston-based Helix Nanotechnologies to develop a new generation of vaccines that remain stable at room temperatur...

The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus. Philadelphia, Pennsylvania--(Newsfile Corp. - August 4,...

The Company added Congresswoman Cathy McMorris Rodgers & Ajay Raju, Esq. to the Board of Directors.

Executive Chairman & CEO of the Company to Participate in a Fireside Chat Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company")...

Medicus Pharma (NASDAQ:MDCX) announced that it has submitted a formal request to the US Food and Drug Administration (FDA) for a Type C meeting to discuss the clinical development pathway for its diss...

The Company's aim is to seek FDA consent to fast track the Clinical Development Program to treat Basal Cell Carcinoma (BCC) of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-M...